| 000 | 01184 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517000531.0 | ||
| 264 | 0 | _c20180117 | |
| 008 | 201801s 0 0 spa d | ||
| 022 | _a1578-8989 | ||
| 024 | 7 |
_a10.1016/S0025-7753(14)70103-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJódar, Esteban | |
| 245 | 0 | 0 |
_a[Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy]. _h[electronic resource] |
| 260 |
_bMedicina clinica _c2014 |
||
| 300 |
_a12-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide-1 Receptor _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aIncretins _xtherapeutic use |
| 650 | 0 | 4 | _aGlucagon-Like Peptide-1 Receptor Agonists |
| 773 | 0 |
_tMedicina clinica _gvol. 143 Suppl 2 _gp. 12-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0025-7753(14)70103-4 _zAvailable from publisher's website |
| 999 |
_c24289478 _d24289478 |
||